NCT02184312View on ClinicalTrials.gov

Pharmacokinetic Properties of Two Dosages Nevirapine Extended Release (XR) Formulations Compared to VIRAMUNE® Tablet as Well as to Nevirapine XR Tablet in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

July 31, 2008

Conditions
Healthy
Interventions
DRUG

Nevirapine XR low dose

DRUG

Nevirapine XR medium dose

DRUG

Nevirapine XR high dose

DRUG

Nevirapine (VIRAMUNE®)

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02184312 - Pharmacokinetic Properties of Two Dosages Nevirapine Extended Release (XR) Formulations Compared to VIRAMUNE® Tablet as Well as to Nevirapine XR Tablet in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter